Who are Lactobacillus brevis CD2 Lozenges's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): E. coli Nissle suspension, INF108F probiotic, Bifidobacterium animalis subsp. lactis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lactobacillus-brevis-cd2-lozenges.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lactobacillus brevis CD2 Lozenges — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lactobacillus brevis CD2 Lozenges (Lactobacillus brevis CD2 Lozenges) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live biotherapeutic product (probiotic). Area: Immunology / Infectious Disease.

phase 3 Live biotherapeutic product (probiotic) Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Lactobacillus brevis CD2 Lozenges (Lactobacillus brevis CD2 Lozenges) — Next Gen Pharma India Pvt. Ltd.. Lactobacillus brevis CD2 is a probiotic lozenge that colonizes the oral and respiratory tract to modulate local and systemic immune responses.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Lactobacillus brevis CD2 Lozenges TARGET	Lactobacillus brevis CD2 Lozenges	Next Gen Pharma India Pvt. Ltd.	phase 3	Live biotherapeutic product (probiotic)
E. coli Nissle suspension	E. coli Nissle suspension	University of Hohenheim	marketed	Live biotherapeutic product (probiotic)
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
Bifidobacterium animalis subsp. lactis	Bifidobacterium animalis subsp. lactis	University of Sao Paulo	phase 3	Live biotherapeutic product (probiotic)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live biotherapeutic product (probiotic) class)

Massachusetts General Hospital · 1 drug in this class
Next Gen Pharma India Pvt. Ltd. · 1 drug in this class
University of Hohenheim · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lactobacillus brevis CD2 Lozenges — Competitive Intelligence Brief. https://druglandscape.com/ci/lactobacillus-brevis-cd2-lozenges. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab